Orphan Medicinal Products for the Treatment of Pancreatic Cancer: Lessons Learned From Two Decades of Orphan Designation
Pancreatic cancer has a dismal prognosis and only a few treatment options are available. In the European Union, pancreatic cancer classifies as a rare disease, allowing drug developers to apply for orphan medicinal product (OMP) designation. The aim of this study was to provide more detail on OMPs f...
Сохранить в:
| Главные авторы: | , , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Frontiers Media S.A.
2021-12-01
|
| Серии: | Frontiers in Oncology |
| Предметы: | |
| Online-ссылка: | https://www.frontiersin.org/articles/10.3389/fonc.2021.809035/full |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|